International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 4 , Pages 1053-1059 , 15 November 2009

Oropharyngeal Squamous Cell Carcinoma Treated With Radiotherapy or Radiochemotherapy: Prognostic Role of TP53 and HPV Status

  • Carlo Fallai, M.D.

      Affiliations

    • Radiation Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    • Corresponding Author InformationReprint requests to: Carlo Fallai, Radioterapia, Fondazione IRCCS Istituto Nazionale Tumori, via Giacomo Venezian 1, 20133, Milan, Italy. Tel.: (+39)0223902478; Fax: (+39)0223902472
    • ,
  • Federica Perrone, Ph.D.

      Affiliations

    • Pathology Department, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    • ,
  • Lisa Licitra, M.D.

      Affiliations

    • Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    • ,
  • Silvana Pilotti, M.D.

      Affiliations

    • Pathology Department, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    • ,
  • Laura Locati, M.D.

      Affiliations

    • Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    • ,
  • Paolo Bossi, M.D.

      Affiliations

    • Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    • ,
  • Ester Orlandi, M.D.

      Affiliations

    • Radiation Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    • ,
  • Mauro Palazzi, M.D.

      Affiliations

    • Radiation Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    • ,
  • Patrizia Olmi, M.D.

      Affiliations

    • Radiation Oncology Department, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy

Received 30 September 2008 ,Revised 2 December 2008 ,Accepted 2 December 2008.

References 

  1. Blons H, Laurent-Puig P. TP53 and head and neck neoplasms. Hum Mutat. 2003;21:252–257
  2. Alsner J, Sorensen SB, Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol. 2001;59:179–185
  3. Cabelguenne A, Blons H, de Waziers I, et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol. 2000;18:1465–1473
  4. Temam S, Flahault A, Perie S, et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2000;18:385–394
  5. Paz IB, Cook N, Odom-Maryon T, et al. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer. 1997;79:595–604
  6. Kumar B, Cordell KG, Lee JS, et al. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Biol Phys. 2007;69:S109–S111
  7. Sisk EA, Soltys SG, Zhu S, et al. Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck. 2002;24:841–849
  8. Lindel K, Beer KT, Laissue J, et al. Human papillomavirus positive squamous cell carcinoma of the oropharynx: A radiosensitive subgroup of head and neck carcinoma. Cancer. 2001;92:805–813
  9. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261–269
  10. Olmi P, Crispino S, Fallai C, et al. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy—a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003;55:78–92
  11. Fallai C, Bolner A, Signor M, et al. Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx. Tumori. 2006;92:41–54
  12. Birindelli S, Perrone F, Oggionni M, et al. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest. 2001;81:833–844
  13. Licitra L, Perrone F, Bossi P, et al. How high-risk human papillomavirus does affect prognosis of patients with oropharyngeal squamous cell carcinoma primarily treated by surgery. J Clin Oncol. 2006;24:5630–5636
  14. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552–2561
  15. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996;88:1442–1455
  16. Lal P, Pal L, Kumar S, et al. Implications of p53 over-expression in the outcome with radiation in head and neck cancers. J Cancer Res Ther. 2007;3:17–22
  17. Pukkila MJ, Kumpulainen EJ, Virtaniemi JA, et al. Nuclear and cytoplasmic p53 expression in pharyngeal squamous cell carcinoma: prognostic implications. Head Neck. 2002;24:784–791
  18. Sittel C, Ruiz S, Volling P, et al. Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity. Oral Oncol. 1999;35:583–589
  19. Aebersold DM, Beer KT, Laissue J, et al. Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. Int J Radiat Oncol Biol Phys. 2000;48:17–25
  20. Sidari L, Tirelli G, Papanikolla L, et al. Flow cytometry expression of p53 and PCNA in oral/oropharynx carcinomas and their lymph node metastases. Anticancer Res. 2003;23:4127–4132
  21. Raybaud-Diogéne H, Fortin A, Morency R, et al. Markers of radioresistance in squamous cell carcinomas of the head and neck: A clinicopathologic and immunohistochemical study. J Clin Oncol. 1997;15:1030–1038
  22. Bourhis J, Lubin R, Roche B, et al. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996;88:1228–1233
  23. Shin DM, Lee JS, Lippman SM, et al. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996;88:519–529
  24. Lavertu P, Adelstein DJ, Myles J, et al. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy. Laryngoscope. 2001;111:1878–1892
  25. Couture C, Raybaud-Diogéne H, Tetu B, et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer. 2002;94:713–722
  26. Grabenbauer GG, Muhlfriedel C, Rodel F, et al. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48:1041–1050
  27. Otero-Garcia JE, Youssef E, Enamorado II, et al. Prognostic significance of p53 and FHIT in advanced oropharyngeal carcinoma. Am J Otolaryngol. 2004;25:231–239
  28. Taylor D, Koch WM, Zahurak M, et al. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: Correlation with p53 gene alterations. Hum Pathol. 1999;30:1221–1225
  29. Stausbøl-Grøn B, Alsner J, Sørensen SB, et al. Bcl-2/p53 expression and TP53 mutations: Correlations with in vitro radiosensitivity in patients with head and neck squamous cell carcinoma. [abstract] Eur J Cancer. 1997;33(Suppl 8):S23
  30. Williams JR, Zhang Y, Zhou H, et al. A quantitative overview of radiosensitivity of human tumor cells across histological type and TP53 status. Int J Radiat Biol. 2008;84:253–264
  31. Obata A, Eura M, Sasaki J, et al. Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx. Int J Cancer. 2000;89:187–193
  32. Alsner J, Sorensen SB, Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol. 2001;59:179–185
  33. Kuropkat C, Venkatesan TK, Caldarelli DD, et al. Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynx. Auris Nasus Larynx. 2002;29:165–174
  34. Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996;88:1580–1586
  35. Eriksen JG, Alsner J, Steiniche T, et al. The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. Radiother Oncol. 2005;76:135–142
  36. Andrews GA, Xi S, Pomerantz RG, et al. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck. 2004;26:870–877
  37. Bradford CR, Zhu S, Ogawa H, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck. 2003;25:654–661
  38. Bauer JA, Kumar B, Cordell KG, et al. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S106–S108
  39. Hoffmann TK, Sonkoly E, Hauser U, et al. Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol. 2008;44:1100–1109
  40. Cullen KJ, Nikitakis N, Goloubeva O, et al. Effect of elevated expression of GST-π and p53 on prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone: An analysis of RTOG trials 9003 and 9501. [Abstract] J Clin Oncol. 2008;26(Suppl):6013
  41. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944–1956
  42. Lindel K, Beer KT, Laissue J, et al. Human papillomavirus positive squamous cell carcinoma of the oropharynx: A radiosensitive subgroup of head and neck carcinoma. Cancer. 2001;92:805–813
  43. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26:3128–3137
  44. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: Response and survival positively associated with HPV16 copy number. J Clin Oncol. 2008;26:3138–3146
  45. Perrone F, Suardi S, Pastore E, et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2006;12:6643–6651

 Conflict of interest: none.

PII: S0360-3016(09)00368-X

doi: 10.1016/j.ijrobp.2008.12.088

International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 4 , Pages 1053-1059 , 15 November 2009

Article Tools

* Image Usage & Resolution